Behandlungsalternativen für sakrale Chordome

Zusammenfassung

Chordome sind primäre maligne ossäre Tumoren und gehören zu den häufigsten Tumorarten im Sakrum. Die operative Tumorresektion und Radiotherapie sind die Eckpfeiler der Chordomtherapie des Sakrums. Eine komplette Resektion ohne Eröffnen der Tumorkapsel (en bloc Resektion) ist mit der besten Überlebensprognose assoziiert, führt jedoch in einigen Fällen zu einer hohen operativen Morbidität. In diesem Übersichtsartikel beschreiben wir das klinische Krankheitsbild, die Diagnostik, aktuelle Behandlungsalternativen und die wichtigsten entscheidungsrelevanten Faktoren dieser komplexen Tumorerkrankung.

Abstract

Chordomas are primary malignant osseous tumors and are among the most common tumor types in the sacrum. Surgical tumor resection and radiotherapy are the cornerstones of chordoma therapy of the sacrum. Complete resection without opening the tumor capsule (en bloc resection) is associated with the best survival prognosis but results in high operative morbidity in some cases. In this review article, we describe the clinical picture, diagnosis, current treatment alternatives, and key decision-making factors of this complex tumor disease.

Schlüsselwörter

Chordom - Kreuzbein - Behandlung - Resektion - Bestrahlung

Keywords

chordoma - sacrum - treatment - resection - radiotherapy

Publication History

Article published online:
14 November 2022

• Literatur

• 1 Bagley CA, Connors SW, Aoun SG. et al. Recent advances in understanding and managing chordomas: An update. F1000Research 2020; 9: 5-16
• 2 Gerber S, Ollivier L, Leclère J. et al. Imaging of sacral tumours. Skeletal Radiol; 2008; 37: 277-289
• 3 Bakker SH, Jacobs WCH, Pondaag W. et al. Chordoma: a systematic review of the epidemiology and clinical prognostic factors predicting progression-free and overall survival. European Spine Journal. Springer Verlag; 2018; 27: 3043-3058
• 4 Mukherjee D, Chaichana KL, Gokaslan ZL. et al. Survival of patients with malignant primary osseous spinal neoplasms: Results from the Surveillance, Epidemiology, and End Results (SEER) database from 1973 to 2003. J Neurosurg Spine 2011; 14: 143-150
• 5 McMaster ML, Goldstein AM, Bromley CM. et al. Chordoma: Incidence and survival patterns in the United States, 1973–1995. Cancer Causes Control 2001; 12: 1-11
• 6 Hu Y, Singh R, Deng Z. et al. Liposome-protamine-DNA nanoparticle-mediated delivery of short hairpin RNA targeting brachyury inhibits chordoma cell growth. J Biomed Nanotechnol 2016; 12: 1952-1961
• 7 Kispert A, Koschorz B, Herrmann BG. The T protein encoded by Brachyury is a tissue-specific transcription factor. EMBO J 1995; 14: 4763-4772
• 8 Karpathiou G, Dumollard JM, Dridi M. et al. Chordomas: A review with emphasis on their pathophysiology, pathology, molecular biology, and genetics. Pathology Research and Practice 2020; 216: 153089
• 9 Pillai S, Govender S. Sacral chordoma: A review of literature. Journal of Orthopaedics 2018; 15: 679-684
• 10 Sommer J. Building a global consensus approach to chordoma: a position paper from the medical and patient community. The Lancet Oncology 2015; 16: e71-e83
• 11 Bergh P, Kindblom LG, Gunterberg B. et al. Prognostic factors in chordoma of the sacrum and mobile spine: A study of 39 patients. Cancer 2000; 88: 2122-2134
• 12 Stacchiotti S, Gronchi A, Fossati P. et al. Best practices for the management of local-regional recurrent chordoma: A position paper by the Chordoma Global Consensus Group. Annals of Oncology 2017; 28: 1230-1242
• 13 Radaelli S, Stacchiotti S, Ruggieri P. et al. Sacral Chordoma: Long-term outcome of a large series of patients surgically treated at two reference centers. Spine 2016; 41: 1049-1057
• 14 Yang Y, Niu X, Li Y. et al. Recurrence and survival factors analysis of 171 cases of sacral chordoma in a single institute. Eur Spine J 2017; 26: 1910-1916
• 15 Dea N, Fisher CG, Reynolds JJ. et al. Current treatment strategy for newly diagnosed chordoma of the mobile spine and sacrum: Results of an international survey. J Neurosurg Spine 2019; 30: 119-125
• 16 Kayani B, Sewell MD, Tan KA. et al. Prognostic Factors in the Operative Management of Sacral Chordomas. World Neurosurg 2015; 84: 1354-1361
• 17 Colangeli S, Muratori F, Bettini L. et al. Surgical Treatment of Sacral Chordoma: En Bloc Resection with Negative Margins is a Determinant of the Long-Term Outcome. Surg Technol Int 2018; 33: 343-348
• 18 Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res 1986; 9-24
• 19 Dekutoski MB, Clarke MJ, Rose P. et al. Osteosarcoma of the spine: Prognostic variables for local recurrence and overall survival, a multicenter ambispective study. J Neurosurg Spine 2016; 25: 59-68
• 20 Fisher CG, Saravanja DD, Dvorak MF. et al. Surgical management of primary bone tumors of the spine: Validation of an approach to enhance cure and reduce local recurrence. Spine 2011; 36: 830-836
• 21 Pombo B, Cristina Ferreira A, Cardoso P. et al. Clinical effectiveness of Enneking appropriate versus Enneking inappropriate procedure in patients with primary osteosarcoma of the spine: a systematic review with meta-analysis. European Spine Journal 2020; 29: 238-247
• 22 Fourney DR, Rhines LD, Hentschel SJ. et al. En bloc resection of primary sacral tumors: classification of surgical approaches and outcome. J Neurosurg Spine (Phila Pa 1976) 2005; 3: 111-122
• 23 Garofalo F, Christoforidis D, Di Summa PG. et al. The unresolved case of sacral chordoma: From misdiagnosis to challenging surgery and medical therapy resistance. Ann Coloproctol 2014; 30: 122-131
• 24 Barber SM, Sadrameli SS, Lee JJ. et al. Chordoma—Current Understanding and Modern Treatment Paradigms. J Clin Med 2021; 10: 1054
• 25 Muneer M, Badran S, Al-Hetmi T. A rare presentation of axial chordoma and the approach to management. Am J Case Rep 2019; 20: 773-775
• 26 Dial BL, Kerr DL, Lazarides AL. et al. The Role of Radiotherapy for Chordoma Patients Managed with Surgery: Analysis of the National Cancer Database. Spine (Phila Pa 1976) 2020; 45: E742-E751
• 27 Jin CJ, Berry-Candelario J, Reiner AS. et al. Long-term outcomes of high-dose single-fraction radiosurgery for chordomas of the spine and sacrum. J Neurosurg Spine 2020; 32: 79-88
• 28 Pennington Z, Ehresman J, Elsamadicy AA. et al. Systematic review of charged-particle therapy for chordomas and sarcomas of the mobile spine and sacrum. Neurosurg Focus 2021; 50: 1-16
• 29 Yolcu YU, Zreik J, Wahood W. et al. Comparison of Oncologic Outcomes and Treatment-Related Toxicity of Carbon Ion Radiotherapy and en Bloc Resection for Sacral Chordoma. JAMA Netw Open 2022; 5: e2141927
• 30 Italian Sarcoma Group. Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease (SACRO). NCT02986516. Accessed September 19, 2022 at: https://clinicaltrials.gov/ct2/show/NCT02986516
• 31 Herfarth K. Ion Irradiation of Sacrococcygeal Chordoma (ISAC). Clinical trial NCT01811394. Accessed September 19, 2022 at: https://clinicaltrials.gov/ct2/show/NCT01811394
• 32 Bostel T, Mattke M, Nicolay NH. et al. High-dose carbon-ion based radiotherapy of primary and recurrent sacrococcygeal chordomas: Long-term clinical results of a single particle therapy center. Radiat Oncol 2020; 15: 206
• 33 Gill CM, Fowkes M, Shrivastava RK. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era. Clinical Neurosurgery 2020; 86: E118-E123
• 34 Demaria PJ, Lee-Wisdom K, Donahue RN. et al. Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. J Immunother Cancer 2021; 9: e003238
• 35 Meng T, Jin J, Jiang C. et al. Molecular targeted therapy in the treatment of chordoma: A systematic review. Frontiers in Oncology 2019; 9: 1-27
• 36 Phimolsarnti R, Waikakul S. Prevalence of neuropathic pain after radical sacral chordoma resection: an observational cohort study with 10-year follow-up. Eur J Orthop Surg Traumatol 2015; 25: 225-231